Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:528-535
© 1997 American Heart Association, Inc.
Articles |
7E3 Monoclonal Antibody Directed Against the Platelet Glycoprotein IIb/IIIa Cross-reacts With the Leukocyte Integrin Mac-1 and Blocks Adhesion to Fibrinogen and ICAM-1
From the Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (D.I.S., H.X., C.R., N.K.R.); Celltech Therapeutics Ltd, Slough, UK (S.O.); and Harvard-MIT Division of Health Sciences and Technology, Cambridge, Mass (C.R.).
Correspondence to Daniel I. Simon, MD, Cardiovascular Division PBB-A3, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. E-mail disimon{at}bics.bwh.harvard.edu.
Abstract Recent clinical trials suggest that blockade of
integrins is a promising strategy for the treatment of acute coronary
syndromes. Administration of 7E3 monoclonal antibody (mAb) Fab fragment
(c7E3 Fab) directed against platelet integrin IIb/IIIa (
IIbß3,
CD41/CD61) reduces acute ischemic complications of coronary
angioplasty and clinical restenosis at 6 months. However, 7E3 mAb is
not selective for platelet IIb/IIIa but also cross-reacts with the
leukocyte integrin Mac-1 (Mß2, CD11b/CD18) and the vitronectin
receptor (vß3, CD51/CD61). Information regarding how this mAb may
affect other cells important in vascular repair is scant. Potential
interactions of c7E3 Fab with inflammatory (ie, monocytes and
neutrophils), vascular smooth muscle, and endothelial cells may
contribute to the in vivo actions of c7E3 Fab. In this study we
explored the binding of 7E3 to monocytic cells and the functional
effect of 7E3 and c7E3 Fab on Mac-1–mediated adhesion to fibrinogen
(FGN) and intercellular adhesion molecule-1 (ICAM-1), ligands abundant
in the injured vessel wall. Flow cytometry demonstrated that 7E3 bound
to THP-1 monocytic cells and identified a subpopulation (
10%) of
Mac-1 that was qualitatively similar to that recognized by CBRM1/5, a
mAb directed to an activation-specific neoepitope present on a subset
of Mac-1 molecules. mAb 7E3 bound to K562 cells transfected with just
the subunit (CD11b) of Mac-1 but not to nontransfected cells,
confirming a direct interaction between 7E3 and Mac-1. mAb 7E3 and c7E3
Fab blocked the adhesion of Mac-1–bearing cells to FGN (80±11% and
78±9% inhibition, respectively) and ICAM-1 (62±14% and 62±17%).
Both 7E3 and c7E3 Fab significantly inhibited (70±6% and 62±26%)
soluble FGN binding to human peripheral blood monocytes. Thus, c7E3 Fab
cross-reacts with the CD11b subunit of Mac-1 and interrupts
cell-extracellular matrix and cell-cell adhesive interactions and may
thereby influence the recruitment of circulating monocytes to sites of
vessel injury. Given the recent evidence that adherent and infiltrating
monocyte number directly correlates with the extent of neointimal
hyperplasia, inhibition of Mac-1–dependent adhesion and
IIb/IIIa-dependent function by c7E3 Fab may jointly contribute to the
regulation of vascular repair and to the sustained clinical benefits
observed with c7E3 Fab after angioplasty.
Key Words: integrins • monocytes • cellular adhesion • restenosis • monoclonal antibody
This article has been cited by other articles:
 |
|
 |
|
  Y. Orr, J. M. Taylor, S. Cartland, P. G. Bannon, C. Geczy, and L. Kritharides Conformational activation of CD11b without shedding of L-selectin on circulating human neutrophils J. Leukoc. Biol., November 1, 2007; 82(5): 1115 - 1125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Gupta, A. Gylling, J. L. Alonso, T. Sugimori, P. Ianakiev, J.-P. Xiong, and M. Amin Arnaout The {beta}-tail domain ({beta}TD) regulates physiologic ligand binding to integrin CD11b/CD18 Blood, April 15, 2007; 109(8): 3513 - 3520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Maioli, F. Bellandi, M. Leoncini, A. Toso, and R. P. Dabizzi Randomized Early Versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx-AMI Trial) J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1517 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Antoniucci Differences among GP IIb/IIIa inhibitors: different clinical benefits in non-ST-segment elevation acute coronary syndrome percutaneous coronary intervention patients Eur. Heart J. Suppl., February 1, 2007; 9(suppl_A): A32 - A36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V K Bhatia and C Di Mario Darwin and the survival of the fittest in modern interventional cardiology Heart, August 1, 2006; 92(8): 1017 - 1018. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Harokopakis, M. H. Albzreh, M. H. Martin, and G. Hajishengallis TLR2 Transmodulates Monocyte Adhesion and Transmigration via Rac1- and PI3K-Mediated Inside-Out Signaling in Response to Porphyromonas gingivalis Fimbriae. J. Immunol., June 15, 2006; 176(12): 7645 - 7656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sharma, R. Makkar, and J. Lardizabal Intracoronary Administration of Abciximab During Percutaneous Coronary Interventions: Should This Be the Routine and Preferred Approach? Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2006; 11(2): 136 - 141. [Abstract] [PDF]
|
|
|
|
|
|
W. Kim, M. H. Jeong, K. H. Kim, I. S. Sohn, Y. J. Hong, H. W. Park, J. H. Kim, Y. K. Ahn, J. G. Cho, J. C. Park, et al. The Clinical Results of a Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab: ReoPro)-Coated Stent in Acute Myocardial Infarction J. Am. Coll. Cardiol., March 7, 2006; 47(5): 933 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Touat, V. Ollivier, J. Dai, M.-G. Huisse, A. Bezeaud, U. Sebbag, T. Palombi, P. Rossignol, O. Meilhac, M.-C. Guillin, et al. Renewal of Mural Thrombus Releases Plasma Markers and Is Involved in Aortic Abdominal Aneurysm Evolution Am. J. Pathol., March 1, 2006; 168(3): 1022 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-L. Hang, C.-P. Wang, H.-K. Yip, C.-H. Yang, G. B.-F. Guo, C.-J. Wu, and S.-M. Chen Early Administration of Intracoronary Verapamil Improves Myocardial Perfusion During Percutaneous Coronary Interventions for Acute Myocardial Infarction Chest, October 1, 2005; 128(4): 2593 - 2598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ferenc and F.-J. Neumann Efficacy of primary PCI: the microvessel perspective Eur. Heart J. Suppl., October 1, 2005; 7(suppl_I): I4 - I9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sciagra, G. Parodi, A. Pupi, A. Migliorini, R. Valenti, G. Moschi, G. M. Santoro, G. Memisha, and D. Antoniucci Gated SPECT Evaluation of Outcome After Abciximab-Supported Primary Infarct Artery Stenting for Acute Myocardial Infarction: The Scintigraphic Data of the Abciximab and Carbostent Evaluation (ACE) Randomized Trial J. Nucl. Med., May 1, 2005; 46(5): 722 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Heinzelmann and H. Bosshart Heparin Binds to Lipopolysaccharide (LPS)-Binding Protein, Facilitates the Transfer of LPS to CD14, and Enhances LPS-Induced Activation of Peripheral Blood Monocytes J. Immunol., February 15, 2005; 174(4): 2280 - 2287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mehilli, A. Kastrati, H. Schuhlen, A. Dibra, F. Dotzer, N. von Beckerath, H. Bollwein, J. Pache, J. Dirschinger, P. P. Berger, et al. Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel Circulation, December 14, 2004; 110(24): 3627 - 3635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T Dirksen, G. Laarman, A. W.J van 't Hof, G. Guagliumi, W. A.L Tonino, L. Tavazzi, D. J.G.M Duncker, M. L Simoons, and on behalf of the PARI-MI Investigators The effect of ITF-1697 on reperfusion in patients undergoing primary angioplasty: Safety and efficacy of a novel tetrapeptide, ITF-1697 Eur. Heart J., March 1, 2004; 25(5): 392 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Chaves, A. G.M.R. Sousa, L. A. Mattos, A. Abizaid, R. Staico, F. Feres, M. Centemero, L. F. Tanajura, A. Abizaid, I. Pinto, et al. Volumetric Analysis of In-Stent Intimal Hyperplasia in Diabetic Patients Treated With or Without Abciximab: Results of the Diabetes Abciximab steNT Evaluation (DANTE) Randomized Trial Circulation, February 24, 2004; 109(7): 861 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S Vasudevan, N. H.M Lopes, P. N Seshiah, T. Wang, C. B Marsh, D. J Kereiakes, C. Dong, and P. J Goldschmidt-Clermont Mac-1 and Fas activities are concurrently required for execution of smooth muscle cell death by M-CSF-stimulated macrophages Cardiovasc Res, September 1, 2003; 59(3): 723 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wohrle, O. C. Grebe, T. Nusser, E. Al-Khayer, S. Schaible, M. Kochs, V. Hombach, and M. Hoher Reduction of Major Adverse Cardiac Events With Intracoronary Compared With Intravenous Bolus Application of Abciximab in Patients With Acute Myocardial Infarction or Unstable Angina Undergoing Coronary Angioplasty Circulation, April 15, 2003; 107(14): 1840 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Lincoff Important Triad in Cardiovascular Medicine: Diabetes, Coronary Intervention, and Platelet Glycoprotein IIb/IIIa Receptor Blockade Circulation, March 25, 2003; 107(11): 1556 - 1559. [Full Text] [PDF]
|
|
|
|
|
|
A.S Petronio, D Rovai, G Musumeci, R Baglini, C Nardi, U Limbruno, C Palagi, D Volterrani, and M Mariani Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty Eur. Heart J., January 1, 2003; 24(1): 67 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Neumann and N. Jander How to best counteract the enemies? By ensuring adequate oxygen delivery Eur. Heart J. Suppl., November 1, 2002; 4(suppl_G): G35 - G42. [Abstract] [PDF]
|
|
|
|
|
|
E. D. Aymong, M. J. Curtis, M. Youssef, M. M. Graham, L. Shewchuk, W. Leschuk, and T. J. Anderson Abciximab Attenuates Coronary Microvascular Endothelial Dysfunction After Coronary Stenting Circulation, June 25, 2002; 105(25): 2981 - 2985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Roffi, D. J. Moliterno, B. Meier, E. R. Powers, C. L. Grines, P. M. DiBattiste, H. C. Herrmann, M. Bertrand, K. E. Harris, L. A. Demopoulos, et al. Impact of Different Platelet Glycoprotein IIb/IIIa Receptor Inhibitors Among Diabetic Patients Undergoing Percutaneous Coronary Intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-Year Follow-Up Circulation, June 11, 2002; 105(23): 2730 - 2736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Seshiah, D. J. Kereiakes, S. S. Vasudevan, N. Lopes, B. Y. Su, N. A. Flavahan, and P. J. Goldschmidt-Clermont Activated Monocytes Induce Smooth Muscle Cell Death: Role of Macrophage Colony-Stimulating Factor and Cell Contact Circulation, January 15, 2002; 105(2): 174 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Baran, M. Nguyen, G. R. McKendall, C. T. Lambrew, G. Dykstra, S. T. Palmeri, R. J. Gibbons, S. Borzak, B. E. Sobel, S. G. Gourlay, et al. Double-Blind, Randomized Trial of an Anti-CD18 Antibody in Conjunction With Recombinant Tissue Plasminogen Activator for Acute Myocardial Infarction: Limitation of Myocardial Infarction Following Thrombolysis in Acute Myocardial Infarction (LIMIT AMI) Study Circulation, December 4, 2001; 104(23): 2778 - 2783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Salter, C. F. Krieglstein, A. C. Issekutz, and D. N. Granger Platelets modulate ischemia/reperfusion-induced leukocyte recruitment in the mesenteric circulation Am J Physiol Gastrointest Liver Physiol, December 1, 2001; 281(6): G1432 - G1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Fintel From bench to bedside: GP IIb-IIIa inhibitors Neurology, September 1, 2001; 57(90002): S12 - 19. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. S. Mahoney, A. S. Weyrich, D. A. Dixon, T. McIntyre, S. M. Prescott, and G. A. Zimmerman Cell adhesion regulates gene expression at translational checkpoints in human myeloid leukocytes PNAS, August 17, 2001; (2001) 181201398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Lincoff, D. J. Kereiakes, M. A. Mascelli, L. I. Deckelbaum, E. S. Barnathan, K. K. Patel, B. Frederick, M. T. Nakada, and E. J. Topol Abciximab Suppresses the Rise in Levels of Circulating Inflammatory Markers After Percutaneous Coronary Revascularization Circulation, July 10, 2001; 104(2): 163 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ludemann, K.-L. Schulte, O. Hader, S. Brehme, H.-D. Volk, and W.-D. Docke Leukocyte/Endothelium Activation and Interactions During Femoral Percutaneous Transluminal Angioplasty Vascular and Endovascular Surgery, July 1, 2001; 35(4): 293 - 301. [Abstract] [PDF]
|
|
|
|
|
|
K. M. Anderson, R. M. Califf, G. W. Stone, F.-J. Neumann, G. Montalescot, D. P. Miller, J. J. Ferguson III, J. T. Willerson, H. F. Weisman, and E. J. Topol Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2059 - 2065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Forsyth, D. A. Solovjov, T. P. Ugarova, and E. F. Plow Integrin {alpha}M{beta}2-mediated Cell Migration to Fibrinogen and Its Recognition Peptides J. Exp. Med., May 14, 2001; 193(10): 1123 - 1134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Neumann, W. Hochholzer, G. Pogatsa-Murray, A. Schomig, and M. Gawaz Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1323 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kupatt, H. Habazettl, P. Hanusch, R. Wichels, D. Hahnel, B. F. Becker, and P. Boekstegers c7E3Fab Reduces Postischemic Leukocyte-Thrombocyte Interaction Mediated by Fibrinogen : Implications for Myocardial Reperfusion Injury Arterioscler. Thromb. Vasc. Biol., October 1, 2000; 20(10): 2226 - 2232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Thompson, M. W. Wakelin, K. Y. Larbi, A. Dewar, G. Asimakopoulos, M. A. Horton, M. T. Nakada, and S. Nourshargh Divergent Effects of Platelet-Endothelial Cell Adhesion Molecule-1 and {beta}3 Integrin Blockade on Leukocyte Transmigration In Vivo J. Immunol., July 1, 2000; 165(1): 426 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Neumann, A. Kastrati, C. Schmitt, R. Blasini, M. Hadamitzky, J. Mehilli, M. Gawaz, M. Schleef, M. Seyfarth, J. Dirschinger, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction J. Am. Coll. Cardiol., March 15, 2000; 35(4): 915 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Fredrickson, N. A. Turner, N. S. Kleiman, N. Graziadei, K. Maresh, M. A. Mascelli, M. B. Effron, and L. V. McIntire Effects of Abciximab, Ticlopidine, and Combined Abciximab/Ticlopidine Therapy on Platelet and Leukocyte Function in Patients Undergoing Coronary Angioplasty Circulation, March 14, 2000; 101(10): 1122 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Chandrasekar and J.-F. Tanguay Platelets and restenosis J. Am. Coll. Cardiol., March 1, 2000; 35(3): 555 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Romberger, P. Heires, S. I. Rennard, and T. A. Wyatt beta -Adrenergic agonist modulation of monocyte adhesion to airway epithelial cells in vitro Am J Physiol Lung Cell Mol Physiol, January 1, 2000; 278(1): L139 - L147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Nurden, C. Poujol, C. Durrieu-Jais, and P. Nurden Platelet Glycoprotein IIb/IIIa Inhibitors : Basic and Clinical Aspects Arterioscler. Thromb. Vasc. Biol., December 1, 1999; 19(12): 2835 - 2840. [Full Text] [PDF]
|
|
|
|
|
|
C. P. Cannon Overcoming thrombolytic resistance: Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1395 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Neumann, D. Zohlnhofer, L. Fakhoury, I. Ott, M. Gawaz, and A. Schomig Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1420 - 1426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Peter, M. Schwarz, C. Conradt, T. Nordt, M. Moser, W. Kubler, and C. Bode Heparin Inhibits Ligand Binding to the Leukocyte Integrin Mac-1 (CD11b/CD18) Circulation, October 5, 1999; 100(14): 1533 - 1539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Acute Platelet Inhibition With Abciximab Does Not Reduce In-Stent Restenosis (ERASER Study) Circulation, August 24, 1999; 100(8): 799 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Scarborough, N. S. Kleiman, and D. R. Phillips Platelet Glycoprotein IIb/IIIa Antagonists : What Are the Relevant Issues Concerning Their Pharmacology and Clinical Use? Circulation, July 27, 1999; 100(4): 437 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Mickelson, M. N. Ali, N. S. Kleiman, N. M. Lakkis, T. W. Chow, B. J. Hughes, and C. W. Smith Chimeric 7e3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty J. Am. Coll. Cardiol., January 1, 1999; 33(1): 97 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Neumann, R. Blasini, C. Schmitt, E. Alt, J. Dirschinger, M. Gawaz, A. Kastrati, and A. Schomig Effect of Glycoprotein IIb/IIIa Receptor Blockade on Recovery of Coronary Flow and Left Ventricular Function After the Placement of Coronary-Artery Stents in Acute Myocardial Infarction Circulation, December 15, 1998; 98(24): 2695 - 2701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Li, P. Rieu, D. L. Griffith, D. Scott, and M. Amin Arnaout Two Functional States of the CD11b A-Domain: Correlations with Key Features of Two Mn2+-complexed Crystal Structures J. Cell Biol., December 14, 1998; 143(6): 1523 - 1534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Deitch, J. K. Williams, M. R. Adams, C. A. Fly, D. M. Herrington, R. E. Jordan, M. T. Nakada, J. A. Jakubowski, and R. L. Geary Effects of ß3-Integrin Blockade (c7E3) on the Response to Angioplasty and Intra-Arterial Stenting in Atherosclerotic Nonhuman Primates Arterioscler. Thromb. Vasc. Biol., November 1, 1998; 18(11): 1730 - 1737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rogers, E. R. Edelman, and D. I. Simon A mAb to the beta 2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits PNAS, August 18, 1998; 95(17): 10134 - 10139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Plescia, M. S. Conte, G. VanMeter, G. Ambrosini, and D. C. Altieri Molecular Identification of the Cross-reacting Epitope on alpha Mbeta 2 Integrin I Domain Recognized by Anti-alpha IIbbeta 3 Monoclonal Antibody 7E3 and Its Involvement in Leukocyte Adherence J. Biol. Chem., August 7, 1998; 273(32): 20372 - 20377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Mahoney, A. S. Weyrich, D. A. Dixon, T. McIntyre, S. M. Prescott, and G. A. Zimmerman Cell adhesion regulates gene expression at translational checkpoints in human myeloid leukocytes PNAS, August 28, 2001; 98(18): 10284 - 10289. [Abstract] [Full Text] [PDF]
|
|